Radiation therapy for malignant melanoma

F. B. Geara, Kie-Kian Ang

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Sufficient biologic and clinical evidence now exists to refute the longstanding dogma that melanomas are uniformly radiation resistant and hence radiation therapy has little role in the management of this disease. Although surgery remains the treatment of choice for the vast majority of localized melanomas, available data indicate that radiation therapy is a viable alternative for a few subsets of patients in whom surgery would result in cosmetic or functional deformity, such as patients with large facial lentigo maligna melanomas or small or intermediate-sized uveal melanomas. Retrospective and Phase II prospective studies have revealed that elective/adjunctive radiation therapy improves the local-regional control rate in patients with thick primary lesions, nodal involvement, or mucosal melanomas. However, the impact of elective/adjunctive radiation therapy on the survival rate has yet to be determined. Radiation therapy has been established as a simple and cost-effective treatment modality for palliation of patients with symptomatic metastatic spread. The response of metastatic deposits to radiation varies with the tumor volume, total dose, and dose per fraction. The choice of optimal fractionation depends on tumor site and the patient's survival expectation. New data indicate that hyperthermia enhances the response of metastatic lesions to radiation. Ongoing research with a variety of experimental strategies may offer the possibility of further increasing the utility of radiation therapy in the management of this disease.

Original languageEnglish (US)
Pages (from-to)1383-1398
Number of pages16
JournalSurgical Clinics of North America
Volume76
Issue number6
DOIs
StatePublished - Jan 1 1996

Fingerprint

Melanoma
Radiotherapy
Radiation
Disease Management
Hutchinson's Melanotic Freckle
Tumor Burden
Cosmetics
Health Care Costs
Fever
Survival Rate
Prospective Studies
Survival
Research
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Surgery

Cite this

Radiation therapy for malignant melanoma. / Geara, F. B.; Ang, Kie-Kian.

In: Surgical Clinics of North America, Vol. 76, No. 6, 01.01.1996, p. 1383-1398.

Research output: Contribution to journalArticle

Geara, F. B. ; Ang, Kie-Kian. / Radiation therapy for malignant melanoma. In: Surgical Clinics of North America. 1996 ; Vol. 76, No. 6. pp. 1383-1398.
@article{1dfc2192646e476c8e9b7e9e98753fe6,
title = "Radiation therapy for malignant melanoma",
abstract = "Sufficient biologic and clinical evidence now exists to refute the longstanding dogma that melanomas are uniformly radiation resistant and hence radiation therapy has little role in the management of this disease. Although surgery remains the treatment of choice for the vast majority of localized melanomas, available data indicate that radiation therapy is a viable alternative for a few subsets of patients in whom surgery would result in cosmetic or functional deformity, such as patients with large facial lentigo maligna melanomas or small or intermediate-sized uveal melanomas. Retrospective and Phase II prospective studies have revealed that elective/adjunctive radiation therapy improves the local-regional control rate in patients with thick primary lesions, nodal involvement, or mucosal melanomas. However, the impact of elective/adjunctive radiation therapy on the survival rate has yet to be determined. Radiation therapy has been established as a simple and cost-effective treatment modality for palliation of patients with symptomatic metastatic spread. The response of metastatic deposits to radiation varies with the tumor volume, total dose, and dose per fraction. The choice of optimal fractionation depends on tumor site and the patient's survival expectation. New data indicate that hyperthermia enhances the response of metastatic lesions to radiation. Ongoing research with a variety of experimental strategies may offer the possibility of further increasing the utility of radiation therapy in the management of this disease.",
author = "Geara, {F. B.} and Kie-Kian Ang",
year = "1996",
month = "1",
day = "1",
doi = "10.1016/S0039-6109(05)70521-1",
language = "English (US)",
volume = "76",
pages = "1383--1398",
journal = "Surgical Clinics of North America",
issn = "0039-6109",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Radiation therapy for malignant melanoma

AU - Geara, F. B.

AU - Ang, Kie-Kian

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Sufficient biologic and clinical evidence now exists to refute the longstanding dogma that melanomas are uniformly radiation resistant and hence radiation therapy has little role in the management of this disease. Although surgery remains the treatment of choice for the vast majority of localized melanomas, available data indicate that radiation therapy is a viable alternative for a few subsets of patients in whom surgery would result in cosmetic or functional deformity, such as patients with large facial lentigo maligna melanomas or small or intermediate-sized uveal melanomas. Retrospective and Phase II prospective studies have revealed that elective/adjunctive radiation therapy improves the local-regional control rate in patients with thick primary lesions, nodal involvement, or mucosal melanomas. However, the impact of elective/adjunctive radiation therapy on the survival rate has yet to be determined. Radiation therapy has been established as a simple and cost-effective treatment modality for palliation of patients with symptomatic metastatic spread. The response of metastatic deposits to radiation varies with the tumor volume, total dose, and dose per fraction. The choice of optimal fractionation depends on tumor site and the patient's survival expectation. New data indicate that hyperthermia enhances the response of metastatic lesions to radiation. Ongoing research with a variety of experimental strategies may offer the possibility of further increasing the utility of radiation therapy in the management of this disease.

AB - Sufficient biologic and clinical evidence now exists to refute the longstanding dogma that melanomas are uniformly radiation resistant and hence radiation therapy has little role in the management of this disease. Although surgery remains the treatment of choice for the vast majority of localized melanomas, available data indicate that radiation therapy is a viable alternative for a few subsets of patients in whom surgery would result in cosmetic or functional deformity, such as patients with large facial lentigo maligna melanomas or small or intermediate-sized uveal melanomas. Retrospective and Phase II prospective studies have revealed that elective/adjunctive radiation therapy improves the local-regional control rate in patients with thick primary lesions, nodal involvement, or mucosal melanomas. However, the impact of elective/adjunctive radiation therapy on the survival rate has yet to be determined. Radiation therapy has been established as a simple and cost-effective treatment modality for palliation of patients with symptomatic metastatic spread. The response of metastatic deposits to radiation varies with the tumor volume, total dose, and dose per fraction. The choice of optimal fractionation depends on tumor site and the patient's survival expectation. New data indicate that hyperthermia enhances the response of metastatic lesions to radiation. Ongoing research with a variety of experimental strategies may offer the possibility of further increasing the utility of radiation therapy in the management of this disease.

UR - http://www.scopus.com/inward/record.url?scp=0030480319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030480319&partnerID=8YFLogxK

U2 - 10.1016/S0039-6109(05)70521-1

DO - 10.1016/S0039-6109(05)70521-1

M3 - Article

C2 - 8977557

AN - SCOPUS:0030480319

VL - 76

SP - 1383

EP - 1398

JO - Surgical Clinics of North America

JF - Surgical Clinics of North America

SN - 0039-6109

IS - 6

ER -